DEA Clarifies That The Synthetic Cannabis Compound HHC Is Federally Banned, And Doesn’t Count As Legal Hemp

DEA Clarifies Synthetic Cannabinoid HHC Is Federally Illegal

The Drug Enforcement Administration (DEA) has issued a formal notice confirming that hexahydrocannabinol (HHC), a cannabinoid produced synthetically from cannabis‑derived components, remains a Schedule I controlled substance under the Controlled Substances Act (CSA). While HHC occurs only in trace amounts in the cannabis plant, it is most commonly manufactured by hydrogenating cannabidiol (CBD) and is sometimes sprayed onto low‑THC hemp flower to mimic the psychoactive effects of delta‑9 THC.

How the 2018 Farm Bill Defines Legal Hemp

The 2018 Farm Bill legalized hemp and its derivatives, provided they contain no more than 0.3 percent delta‑9 THC on a dry‑weight basis. Crucially, the exemption applies only to naturally occurring cannabinoids found in the plant. In its latest Federal Register filing, the DEA emphasizes that synthetically produced tetrahydrocannabinols—including HHC—do not qualify as “tetrahydrocannabinols in hemp” and therefore fall outside the Farm Bill’s protection.

As the agency states: “Only tetrahydrocannabinols in or derived from the cannabis plant—not synthetic tetrahydrocannabinols—are excluded from control as ‘tetrahydrocannabinols in hemp.’” This clarification aligns with an earlier 2023 letter from Terrance Boos, chief of the DEA’s Drug and Chemical Evaluation Section, which noted that HHC “does not occur naturally in the cannabis plant and can only be obtained synthetically.”

DEA’s Administrative Action: Unique Drug Code for HHC

Although HHC has long been treated as a Schedule I substance, the DEA’s new rule assigns it a distinct drug code within Schedule I. This administrative step does not alter HHC’s legal status but enables the agency to set aggregate production quotas and allocate individual manufacturing and procurement quotas to DEA‑registered manufacturers. Previously, such quotas were managed under the broader tetrahydrocannabinol code.

The notice also references a recent move by the United Nations Commission on Narcotic Drugs (CND) to place HHC in Schedule II of the 1971 Convention on Psychotropic Substances. The United States abstained from that vote, making it the sole country to oppose the international scheduling decision.

Agreement with Health Authorities and Ongoing Legal Debate

The DEA reports that the U.S. Department of Health and Human Services (HHS) concurs with the direct listing and drug‑code assignment of HHC in the CSA. Despite this federal stance, several appellate courts have challenged the DEA’s interpretation of what constitutes a legal cannabinoid under the Farm Bill, suggesting that the legal landscape remains contested.

Looking ahead, a provision in a recent spending bill signed by President Donald Trump is set to tighten the federal definition of legal hemp. Effective November 12, only hemp products containing up to 0.4 milligrams of total THC per container will remain permissible unless Congress amends or delays the change. Meanwhile, the Trump administration has announced steps to broadly reschedule marijuana under federal law, a development that could further influence how cannabinoids like HHC are regulated.

For readers seeking the original source of this information, see the detailed report from Marijuana Moment: Here.